These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3847274)

  • 41. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.
    Roberts SA; Shore KP; Paviour SD; Holland D; Morris AJ
    J Antimicrob Chemother; 2006 May; 57(5):992-8. PubMed ID: 16507560
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.
    Hoellman DB; Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Mar; 42(3):495-501. PubMed ID: 9517922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cephamycin inactivation due to enzymatic hydrolysis by beta-lactamase from Bacteroides fragilis.
    Yotsuji A; Minami S; Kakizawa H; Yasuda T; Takai A; Saikawa I; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1985 Dec; 28(6):773-7. PubMed ID: 3878690
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria.
    Aldridge KE
    Clin Ther; 1990; 12 Suppl C():3-12. PubMed ID: 2202509
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activity of cefoxitin and parenterally administered cephalosporins against anaerobic bacteria.
    Sutter VL; Kirby B; Finegold SM
    Rev Infect Dis; 1979; 1(1):218-23. PubMed ID: 318226
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I; Warren C; Shannon K; King A; Hanslo D
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of DMG-Mino and DMG-DM Dot, two new glycylcyclines, against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1993 Oct; 12(10):784-6. PubMed ID: 7802861
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Susceptibility of anaerobic bacteria to Sch 34343 and other beta-lactam antibiotics.
    Jacobus NV; Tally FP; Gorbach SL
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():189-91. PubMed ID: 4030547
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antimicrobial susceptibility of anaerobic bacteria in Australia.
    Chen SC; Gottlieb T; Palmer JM; Morris G; Gilbert GL
    J Antimicrob Chemother; 1992 Dec; 30(6):811-20. PubMed ID: 1289355
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Antimicrobial activity of ornidazole and 6 other antibiotics against anaerobic bacteria].
    Alados JC; Martínez-Brocal A; Miranda C; Rojo MD; García V; Domínguez MC; de la Rosa M
    Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):219-22. PubMed ID: 1863621
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.
    Nord CE; Olsson-Liljequist B
    Scand J Infect Dis Suppl; 1984; 43():44-9. PubMed ID: 6100139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Susceptibility of anaerobic bacteria to tosufloxacin.
    Nord CE; Lindmark A; Persson I; Runow C
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):263-5. PubMed ID: 1597207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
    Appelbaum PC; Spangler SK; Jacobs MR
    J Antimicrob Chemother; 1993 Aug; 32(2):223-31. PubMed ID: 8226424
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determination of susceptibility of anaerobic bacteria to cefotetan and cefoxitin by the thioglycolate disk elution method.
    Barry AL; Packer RR
    J Clin Microbiol; 1984 Nov; 20(5):912-6. PubMed ID: 6595259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
    Venezia RA; Yocum DM; Robbiano EM; Echols RM
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1858-61. PubMed ID: 2178340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of imipenem against anaerobic bacteria.
    Wexler HM; Finegold SM
    Rev Infect Dis; 1985; 7 Suppl 3():S417-25. PubMed ID: 3901206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [In vitro activity of a combination of amoxicillin-clavulanic acid on anaerobic bacteria].
    Sedallian A; Roudon T
    Pathol Biol (Paris); 1988 Jun; 36(5 Pt 2):678-81. PubMed ID: 3054746
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antimicrobial susceptibility of clinical isolates of anaerobic bacteria in Ontario, 2010-2011.
    Marchand-Austin A; Rawte P; Toye B; Jamieson FB; Farrell DJ; Patel SN
    Anaerobe; 2014 Aug; 28():120-5. PubMed ID: 24923267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative antimicrobial activity of aminothiazolyl methoxyimino cephalosporins against anaerobic bacteria, including 100 cefoxitin-resistant isolates.
    Jones RN; Barry AL; Aldridge KE; Gerlach EH
    Diagn Microbiol Infect Dis; 1987 Nov; 8(3):157-63. PubMed ID: 3501976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.